Results 121 to 130 of about 10,879 (228)

Pharmacokinetic interactions between simeprevir and ledipasvir in treatment naive hepatitis C virus genotype 1-Infected patients without cirrhosis treated with a simeprevir-sofosbuvir-ledipasvir regimen [PDF]

, 2017
Interactions between simeprevir (hepatitis C virus [HCV] NS3/4A protease inhibitor) and ledipasvir (HCV NS5A replication complex inhibitor) were investigated in treatment-naive HCV genotype 1-infected patients without cirrhosis, treated with simeprevir ...
Beumont, Maria, Bourgeois, Stefan, Hillewaert, Vera, Horsmans, Yves, Luo, Donghan, Moreno, Christophe, Nevens, Frederik, Ouwerkerk-Mahadevan, Sivi, van de Logt, Jolanda, van Eygen, Veerle, Van Remoortere, Pieter, Van Vlierberghe, Hans, Vijgen, Leen   +12 more
core   +2 more sources

Drug Repurposing of Approved Drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine and Ergotamine for Combating COVID19

, 2020
Pneumonia of unknown cause detected in Wuhan, China was first reported to the WHO Country Office in China on 31 December 2019. The outbreak was declared a Public Health Emergency of International Concern on 30 January 2020.
M. Vishal, D. Pravin, Gandhi Himani, Vaghamshi Nilam, Beladiya Urvisha, P. Rajesh   +5 more
semanticscholar   +1 more source

A hepatitis C-vírus-bázispolimorfizmus jelentősége a kezelésben [PDF]

, 2015
Absztrakt A krónikus C-vírus hepatitis kezelése az elmúlt huszonöt évben igen jelentős fejlődésen ment keresztül.
Tornai, István
core   +1 more source

Recent advances in managing chronic HCV infection: Focus on therapy in patients with severe liver disease [PDF]

, 2016
Chronic hepatitis C virus (HCV) infection still represents a major public health problem, as it is thought to be responsible for more than 350,000 deaths around the globe on a yearly basis.
Maan, R. (Raoel), Meer, A.J.P. (Adriaan) van der   +1 more
core   +5 more sources

Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection. [PDF]

, 2020
Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated interferon plus ribavirin. In an open-label study, we evaluated the safety and efficacy of sofosbuvir plus ribavirin for 12 weeks in children aged ...
Balistreri, William F, Bansal, Sanjay, Brainard, Diana M, Davison, Suzanne, Feiterna-Sperling, Cornelia, Gillis, Lynette A, Gonzalez-Peralta, Regino P, Hsueh, Chia-Hsiang, Indolfi, Giuseppe, Jonas, Maureen M, Kelly, Deidre A, Lin, Chuan-Hao, Massetto, Benedetta, Murray, Karen F, Nightingale, Scott, Parhy, Bandita, Rosenthal, Philip, Schwarz, Kathleen B, Shao, Jiang, Sokal, Etienne M, Wirth, Stefan   +20 more
core  

Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients [PDF]

, 2017
Short communication[Abstract] Background. New direct-acting antivirals agents (DAAs) are very safe and well tolerated. Objectives. The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have co-morbidities and ...
Castro-Iglesias, Ángeles, Cid-Silva, Purificación, Delgado, Manuel, Margusino-Framiñán, Luis, Meijide, Héctor, Mena, Álvaro, Morano, Luis, Pedreira, José D., Pernas, Berta, Poveda, Eva, Rodríguez-Osorio, Iria, Suárez, Marta, Tabernilla, Andrés   +12 more
core   +2 more sources

New perspectives for preventing hepatitis C virus liver graft infection [PDF]

, 2016
publisher: Elsevier articletitle: New perspectives for preventing hepatitis C virus liver graft infection journaltitle: The Lancet Infectious Diseases articlelink: http://dx.doi.org/10.1016/S1473-3099(16)00120-1 content_type: article copyright: © 2016 ...
Abdelmalek, Adam, Akazawa, Andre, Audrey Coilly, Bandiera, Bankwitz, Baumert, Benedicto, Berenguer, Berenguer, Berenguer, Berenguer, Bizollon, Blasco, Brown, Bzowej, Carrion, Carrion, Carrion, Chalasani, Charlton, Charlton, Charlton, Charlton, Chung, Ciesek, Coilly, Coilly, Coilly, Colpitts, Colpitts, Crespo, Curry, Curry, Daniel J Felmlee, Davis, de Jong, Denniston, Desombere, Deuffic-Burban, Didier Samuel, Fafi-Kremer, Faisal, Fauvelle, Feld, Felmlee, Firpi, Fofana, Fofana, Fofana, Forman, Forns, Forns, Foster, Foster, Fukasawa, Fukuhara, Gambato, Gane, Gane, Gerold, Guedj, Haberstroh, Haid, He, Helle, Hopcraft, Janssen, Ji, Jiang, Keck, Khan, Kim, Kong, Kugelmas, Kwo, Kwo, Lanford, Law, Leroy, Lin, Lupberger, Mailly, Manns, Manns, Marino, Martin, Martin, Masaki, Mazzaferro, Meuleman, Meuleman, Meuleman, Munoz, O'Shea, Ojo, Ouwerkerk-Mahadevan, Owsianka, Pawlotsky, Perin, Picciotto, Ploss, Ploss, Poordad, Prieto, Pungpapong, Raymond T Chung, Reddy, Roche, Rowe, Rowe, Sainz, Shergill, St Vincent, Sugawara, Sulkowski, Takaki, Terrault, Thomas F Baumert, Toso, Uprichard, Van Der Ree, Vanwolleghem, Veldt, Vercauteren, Vercauteren, von Hahn, Walter, Wang, Watt, Wedemeyer, Welker, Xiao, Xiao, Xirouchakis, Yamashita, Zahid, Zeisel, Zeisel, Zhang, Zhang, Zhu, Zona   +143 more
core   +4 more sources

Effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience

SAGE Open Medicine, 2018
Objective: Successful treatment is possible with novel direct-acting oral antiviral agents in solid organ transplant patients with hepatitis C. In this study, the effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or ...
Mete Akin, Osman Cagin Buldukoglu, Haydar Adanir, Inci Suleymanlar, Dinc Dincer, Bulent Yildirim   +5 more
doaj   +1 more source

HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy

Viruses, 2015
Sustained virological response (SVR) rates have increased dramatically following the approval of direct acting antiviral (DAA) therapies. While individual DAAs have a low barrier to resistance, most patients can be successfully treated using DAA ...
Kazuaki Chayama, C. Nelson Hayes
doaj   +1 more source

An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences

Pathogens
Direct-acting antivirals (DAAs) revolutionized the therapeutics of chronic hepatitis C. The emergence and transmission of HCV variants with resistance-associated substitutions (RASs) can undermine HCV treatment.
Roaa Khalil, Kholoud Al-Mahzoum, Muna Barakat, Malik Sallam   +3 more
doaj   +1 more source